Case report: Immunovirotherapy as a novel add-on treatment in a patient with thoracic NUT carcinoma
Linus D. Kloker, Ulrich M. Lauer(German Cancer Research Center), Branko Calukovic, Susanne Berchtold(University Children's Hospital Tübingen), Abbas Agaimy(Comprehensive Cancer Center Erlangen), Alexander Golf, Mary E. Carter, Julia Beil(German Cancer Research Center), Sandra Mairhofer(Asklepios Fachkliniken München-Gauting), Thomas Duell(Asklepios Fachkliniken München-Gauting), Simone Haas(Max Planck Institute of Biochemistry), Sebastian Böhm(Humboldt-Universität zu Berlin), Niels Reinmuth(Asklepios Fachkliniken München-Gauting), Katrin Benzler, Tina Ganzenmueller(Medizinische Hochschule Hannover), Marius Horger(University of Tübingen), Sven Günther, Stephan Singer(University Children's Hospital Tübingen), Robert Stöhr(Friedrich-Alexander-Universität Erlangen-Nürnberg), Fabian Fohrer(Asklepios Fachkliniken München-Gauting), Arndt Hartmann, Lars Zender(German Cancer Research Center)
Cited by 14
Related Papers
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2019|1.7k
Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations
|New England Journal of Medicine|2020|879
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
|Journal of Clinical Oncology|2021|818
Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies
|JNCI Journal of the National Cancer Institute|2010|716
Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma
|Cancer Cell|2016|660